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ABSTRACT 
Background: The novel influenza A(H1N1pdm09) virus emerged in North America 
in early 2009 and rapidly spread worldwide. In this study we report the efficacy of the 
live attenuated monovalent H1N1pdm09 vaccine and 2009-10 seasonal influenza 
vaccine in a randomized double-blind placebo-controlled trial. 
Methods: We enrolled 703 children aged 7-11. Each child was randomly allocated in 
the ratio 3:2 to receive one dose of live attenuated monovalent H1N1pdm09 vaccine 
or saline placebo between November 2009 and January 2010, followed after 3-10 
weeks by independent random allocation to one dose of live attenuated trivalent 2009-
10 seasonal influenza vaccine or saline placebo in the same ratio. Children were 
followed up through September 2010 with biweekly telephone calls and symptom 
diaries. Seasonal and pandemic influenza infections were confirmed by virologic 
testing of nose and throat swabs collected during acute respiratory illnesses.  
Results: Overall, 30 children had confirmed influenza including 3 (0.43%) 
H1N1pdm09, 10 (1.4%) seasonal A(H3N2), and 17 (2.4%) influenza B. There were 
no significant differences in incidence rates of H1N1pdm09 or A(H3N2) between the 
four study arms, but receipt of the seasonal influenza vaccine was associated with a 
significant reduction in risk of influenza B (p<0.01). Vaccine efficacy against 
confirmed H1N1pdm09 infection associated with receipt of the monovalent 
H1N1pdm09 vaccine was 65% (95% confidence interval, CI: -281%, 97%). Vaccine 
efficacies against confirmed seasonal influenza A(H3N2) and B infection associated 
with receipt of the seasonal influenza vaccine were 31% (95% CI: -138%, 80%) and 
96% (95% CI: 67%, 99%) respectively. 
Conclusions: Vaccine efficacy was consistent with other studies of the monovalent 
H1N1pdm09 vaccine and seasonal influenza vaccines. Our study was underpowered 
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to provide precise estimates of vaccine efficacy due to low incidence of influenza A 
viruses during the study period. 
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INTRODUCTION 
Influenza vaccination is effective in reducing influenza-related morbidity in school-
age children in years when the vaccine strains are well-matched to circulating viruses 
[1,2]. In early 2009 a novel pandemic influenza A(H1N1pdm09) virus emerged in 
North America and rapidly spread to other countries. A monovalent vaccine against 
the novel strain became available after 4-6 months. Preliminary studies confirmed the 
safety, tolerability, and immunogenicity of a monovalent intranasal live attenuated 
H1N1pdm09 vaccine [3]. There is some evidence that the monovalent H1N1pdm09 
vaccine has moderate to high vaccine effectiveness against confirmed infection [4-13]. 
 
We conducted a double-blind placebo-controlled randomized trial to evaluate the 
efficacy of the live attenuated H1N1pdm09 vaccine and 2009-10 seasonal trivalent 
influenza vaccine. 
 
METHODS 
This large school-based double-blind placebo-controlled randomized controlled trial 
was conducted in Hong Kong over a 1-year period from September 2009 through 
September 2010. The primary objective of the study was to evaluate the efficacy of 
vaccinating school-age children against seasonal influenza, H1N1pdm09, or both, in 
reducing confirmed influenza infections among school-age children. The study was 
also designed to investigate indirect benefits of influenza vaccination of study 
subjects to their household contacts and classmates, which will be reported separately.  
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Enrolment, randomization, and follow-up 
We attempted to contact the principals of all 615 primary schools in Hong Kong by 
mail and telephone during the summer of 2009, provided information about our study 
and invited them to participate in our study. In interested schools we organized health 
talks which including an invitation to participate in our study either as stand-alone 
events or as part of school open days during September and October 2010. 
Information regarding the child’s health status was collected from interested parents. 
All children aged 7 to 11 were eligible to participate unless they had asthma or active 
wheezing, a history of hypersensitivity to eggs or other substances in the vaccine or if 
any household member were receiving immunosuppressive agents or had an 
underlying immune-compromised condition. We obtained signed informed consent 
forms from the parents of children who met the inclusion criteria and were willing for 
their child to participate. 
 
Children were randomly allocated to receive either one dose of pandemic influenza 
vaccine or placebo during November and December 2009 at specially arranged in-
school clinics. Individual classes were allocated to blocks of vaccine:placebo in ratios 
of either 4:1 or 2:3 with equal chance, and within classes children were randomized 
within blocks of size 5 so that the overall ratio of vaccine:placebo was 3:2. Allocation 
lists were thus constructed for each of the two strata and used in sequence. The 
motivation for including two strata with differing randomization ratios was to allow 
inferences to be made about indirect benefits of vaccination via comparison of the 
incidence of infections in the control arms across the two strata. After one month all 
study subjects who received H1N1pdm09 vaccine were matched to receive seasonal 
trivalent vaccine, and subjects who received placebo were matched to receive a 
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second dose of placebo. However as a result of improper implementation of the 
randomization scheme, the receipt of seasonal influenza vaccine or placebo occurred 
independently of the original allocation of pandemic vaccine, resulting in four 
randomized study arms: pandemic plus seasonal vaccine, pandemic vaccine plus 
placebo, placebo plus seasonal vaccine, or two placebo doses in the ratio 2:1:1:1 
(16:4:4:1 and 4:6:6:9 in the two strata where vaccine:placebo equals 4:1 and 2:3, 
respectively). 
 
Immediately prior to vaccine administration, a physician confirmed the fitness of each 
study subject to receive vaccine. Subjects were provided with a 7-day adverse 
reaction card following receipt of each vaccine. We arranged to revisit schools at later 
dates to administer vaccines to study subjects who were deemed unfit at the first visit. 
Blinding of study vaccines was achieved by using identical packaging of vaccines and 
placebo in numbered syringes. A research assistant who had no knowledge of 
treatment assignments allotted unique identification codes to each participant. 
Vaccine allocations were not revealed to the subjects, their parents and household 
members, the study team responsible for vaccine administration and subject follow-up, 
or the laboratory staff.  
 
Subjects were provided with symptom diary cards to record signs and symptoms 
associated with acute respiratory illness (ARI) from recruitment to the study until 30 
September 2010. The diary cards were posted back on a monthly basis in prepaid 
envelopes. We conducted biweekly telephone follow-up throughout the follow-up 
period to prospectively identify ARI episodes. Participating households were also 
encouraged to proactively call our study hotline directly if any member was suffering 
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from an ARI. A report of ARI in any household member triggered a home visit from 
one of our study nurses during which nose and throat swabs were collected from all 
household members regardless of illness. Home visits were repeated at 3-day intervals 
until illnesses resolved. Households were compensated with supermarket coupons or 
book tokens worth US$65 for participation in the study. Participants were 
compensated with US$6.5 for each nose and throat swab sample provided. The study 
was approved by the Institutional Review Board of Hong Kong University. 
 
Vaccines and placebos 
We obtained special permission from the Hong Kong Department of Health to import 
the vaccines into Hong Kong for this study. Live attenuated H1N1pdm09 vaccine 
(Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal, MedImmune LLC) 
and trivalent live attenuated 2009-10 seasonal influenza vaccine (FluMist, 
MedImmune LLC) were not licensed in Hong Kong at the start of our study; the 
2010-11 live attenuated seasonal influenza vaccine was subsequently licensed for use 
in Hong Kong. The only influenza vaccines licensed and locally available at the start 
of our study were trivalent inactivated influenza vaccines. A monovalent inactivated 
H1N1pdm09 vaccine became available in January 2010 but community uptake was 
very low. 
 
Each 0.2ml pre-filled refrigerated H1N1pdm09 vaccine sprayer contained 106.5-7.5 
fluorescent focus units of the live attenuated influenza virus reassortant of the 
pandemic virus A/California/7/2009 (H1N1). Each 0.2ml trivalent seasonal influenza 
vaccine sprayer contained 106.5-7.5 fluorescent focus units of live attenuated influenza 
virus reassortants of these three strains for the 2009-10 season: A/South 
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Dakota/6/2007 (H1N1) (A/Brisbane/59/2007-like), A/Uruguay/716/2007 (H3N2) 
(A/Brisbane/10/2007-like), and B/Brisbane/60/2008. Placebos were composed of 
0.2ml saline in identical pre-filled sprayers.  
 
Laboratory methods 
Our protocols for collection of nose and throat swabs during home visits have been 
described in detail elsewhere [14-17]. Following collection, swabs were suspended in 
a tube containing viral transport medium (0.5% bovine serum albumin in Earle’s 
balanced salt solution with antibiotic), stored in an ice box with at least two icepacks, 
and transferred within 3 hours to the central testing laboratory at Queen Mary 
Hospital by courier at 4-8°C. Specimens were eluted and cryopreserved at -70°C 
immediately after receipt in the laboratory prior to testing. Specimens were tested by 
reverse transcription polymerase chain reaction (RT-PCR) for influenza A and B 
viruses and subtyped using standard methods as described previously [14-19]. 
 
Outcome measures 
The primary outcome measures were influenza A or B virus infection confirmed by 
RT-PCR, and the number of episodes of ARI, defined as any 2 of the following 5 
signs or symptoms: fever ≥37.8ºC, cough, headache, sore throat, or myalgia. A 
secondary outcome measure was the number of episodes of febrile acute respiratory 
illness (FARI), defined as fever ≥37.8ºC plus cough or sore throat [14,15]. Thus FARI 
episodes were a subset of ARI episodes. We counted all episodes that were reported 
via symptom diaries or the telephone follow-up from two weeks after receipt of the 
first vaccine (H1N1pdm09) or placebo dose until 30 September 2010, excluding the 
two week period following receipt of the second vaccine (seasonal) or placebo dose. 
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We defined new ARI episodes as episodes that began at least 7 days after the end of a 
previous ARI episode. Vaccine reactogenicity was assessed in terms of 12 signs or 
symptoms measured on a scale of none/mild/moderate/serious for 7 days following 
vaccination. 
 
Statistical analysis 
This study was originally planned as a larger 2-year study with two arms, vaccine 
versus placebo, but these plans were revised in light of the emergence of the 
pandemic. For the purposes of power analysis, if we conservatively assumed no 
synergy or cross-strain protection between vaccines, randomization of 420 children to 
H1N1pdm09 vaccine versus 280 to placebo would allow 80% power to identify 
vaccine efficacy of 50% assuming a cumulative incidence of confirmed H1N1pdm09 
infection of 15% in the placebo arm, or vaccine efficacy of 66% assuming a 
cumulative incidence of 7.5% in the placebo arm. Power would be reduced for lower 
efficacy or lower attack rates. A similar power calculation applies for specific strains 
contained in the seasonal vaccine. Cross-strain protection or synergy between 
vaccines would increase the power of the study to detect the efficacy of one or both 
vaccines. 
 
The proportion of children with a confirmed influenza infection were compared using 
Fisher’s exact tests. Because children could have more than one episode and could 
differ in duration of follow up, the rate of ARI or FARI episodes were modeled using 
Poisson regression and rates between study arms were compared using Wald tests 
from nested models. Confidence intervals for incidence rates were estimated using 
exact Poisson confidence intervals [20]. We estimated vaccine efficacy as (1-
 11 
cumulative incidence ratio)×100. For analyses of vaccine efficacy against confirmed 
influenza B where there was a zero in the numerator, we added 0.5 to each cell before 
calculating the relative rate as an ad-hoc correction [21,22]. Analyses were conducted 
in accordance with the intention to treat principle. For all hypothesis tests, a p-value 
of less than 0.05 was considered statistically significant. All statistical analyses were 
conducted in R version 2.15.1 (R Foundation for Statistical Computing, Vienna, 
Austria).  
 
Role of the funding source 
MedImmune LLC supported the study by providing an unrestricted research grant, 
live attenuated vaccines, and saline nasal sprayers. The funding body had no role in 
study design, data management, analysis or interpretation of the data, or the decision 
to submit for publication. 
 
RESULTS 
The principals of 615 primary schools across Hong Kong were invited to participate, 
50 school principals expressed preliminary interest in our study and 34 schools 
subsequently agreed to participate. Invitation letters were sent to all the parents of 
children aged 7-11 years old in 34 schools. Seven schools discontinued participation 
following a low response rate from parents; the study proceeded in 27 primary 
schools that had a total student population of around 16,300 children. The parents of 
approximately 3,000 children expressed an interest to attend the health talk; 
approximately 1,500 parents attended one of our health talks. The parents of 923 
children provided signed informed consent to participate in our study. Subsequently 
168 children were withdrawn prior to randomization most commonly due to concerns 
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over vaccine safety following media speculation on adverse events associated with 
H1N1pdm09 vaccines, 25 subjects were found to be ineligible most commonly due to 
asthma, and 27 subjects were unfit to receive vaccination for various reasons, the 
most common being current acute respiratory illness.  
 
In total, 703 children were randomized and received a single dose of H1N1pdm09 
vaccine or placebo, and 685 children subsequently received seasonal vaccine or 
placebo. One child was found to be ineligible due to an acute ARI during the 
scheduled appointment for seasonal vaccination, and the parents of 17/703 children 
withdrew from the study after H1N1pdm09 vaccination but prior to administration of 
seasonal vaccination. Five children were lost to follow-up after receipt of seasonal 
vaccine. The number of participating children in any class was no greater than 9 and 
most frequently 1-5 within classes of 26-35 children. In accordance with the 
intention-to-treat principle all 703 randomized children in the four study arms were 
included in subsequent analyses. Figure 1 summarizes the flow of subjects through 
the study.  
 
Baseline characteristics of study subjects were similar across the four arms and the 
majority of children were aged 9-11y (Table 1). Of the children aged ≤8y, 69/229 
(30%) had received influenza vaccination for the preceding 2008-09 season. We 
administered vaccines during the period of low influenza activity prior to a winter 
influenza season dominated by influenza B with some H1N1pdm09 circulation, and a 
summer influenza season later than usual and dominated by drifted A/Perth/16/09-like 
influenza A(H3N2) viruses that were antigenically different to the vaccine A(H3N2) 
strain (Appendix Figure 1). 448/685 (65%) children received the second vaccination 
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21-59 days after the first vaccination, 190/685 (28%) children received the second 
dose after 60-74 days, 46/685 (7%) children received the second vaccination after 75-
92 days, and one child received the second vaccination after a 14-day delay.  
 
No serious adverse events were reported following vaccination, and adverse events 
were uncommon. 85% of all reported adverse events were graded as mild rather than 
moderate. The most frequently reported adverse event following receipt of 
H1N1pdm09 vaccine and seasonal vaccine was nasal congestion (Appendix Figure 2). 
Rates of adverse events were generally higher for the H1N1pdm09 vaccine than the 
seasonal vaccine. There was a statistically significant difference in occurrence of 
nasal congestion, sore throat, abdominal pain and chills between seasonal vaccine and 
placebo, but there were no other statistically significant differences in frequency of 
reported adverse events between vaccines and placebos.  
 
We collected 1,630 nose and throat swabs from 317 study subjects during the follow-
up period, including 1,051 (64%) swabs that were collected during an ARI episode in 
the subject, and 579 collected while a household contact had ARI. 30 children had 
influenza virus infection confirmed by RT-PCR: 3 (0.43%) had H1N1pdm09, 10 
(1.4%) had seasonal A(H3N2), and 17 (2.4%) had influenza B. Of the confirmed 
H1N1pdm09 infections, 2/3 occurred 47 and 35 days after receipt of H1N1pdm09 
vaccine or the matched placebo, respectively, but prior to receipt of seasonal vaccine. 
No confirmed seasonal influenza infections occurred during the window between 
receipt of the two vaccines. There were no statistically significant differences between 
study arms in H1N1pdm09 or H3N2 incidence, but there was a statistically significant 
reduction in influenza B incidence in the study subjects who received the seasonal 
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influenza vaccine (Table 2). Of the confirmed infections, 30 (100%) were associated 
with a reported ARI episode including 27 (90%) associated with a FARI episode. 
Study subjects reported 945 ARI episodes including 383 FARI episodes during the 
follow-up period, with statistically significant differences in all-cause risk of acute 
respiratory illnesses between study arms (Table 2). Results were similar when 
analyses were stratified by age into children aged 7-8 or 9-11 years (data not shown).  
 
Vaccine efficacy estimates are shown in Table 3. Efficacy against confirmed 
H1N1pdm09 of the three individual vaccine arms versus placebo and of the seasonal 
vaccine versus its matched placebo could not be estimated due to the lack of events in 
the corresponding reference arm (Table 3). When comparing study subjects allocated 
to H1N1pdm09 vaccine rather than the matched placebo, regardless of whether they 
subsequently received seasonal vaccine or placebo, the vaccine efficacy against 
confirmed H1N1pdm09 was 65% (95% CI: -281, 97). When comparing study 
subjects allocated to seasonal vaccine rather than the matched placebo, regardless of 
whether they had previously received H1N1pdm09 vaccine or placebo, the vaccine 
efficacy against seasonal influenza A(H3N2) was 31% (95% CI: -138, 80) and against 
influenza B was 96% (95% CI: 67, 99). 
 
DISCUSSION 
In our study the efficacy of H1N1pdm09 LAIV against confirmed H1N1pdm09 
infection was estimated as 65% (95% CI: -281, 97), which is consistent with case-
control studies that have reported effectiveness point estimates of 61% for 
monovalent live attenuated H1N1pdm09 vaccine [4] and 72%-97% against confirmed 
influenza for other H1N1pdm09 vaccines [5-13]. Compared to two doses of placebo, 
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the combination of H1N1pdm09 plus seasonal influenza vaccine was estimated to 
have high efficacy against influenza B (VE=97%, 95% CI: 49, 100). Prior receipt of 
the monovalent H1N1pdm09 vaccine did not appear to reduce the efficacy of the 
seasonal vaccine against influenza B.  
 
Efficacy against seasonal A(H3N2) was less clear with a wide confidence interval 
(VE=29%, 95% CI: -213, 84), similar to the estimates of vaccine efficacy for seasonal 
influenza vaccine regardless of receipt of H1N1pdm09 vaccine or placebo (Table 3). 
While the confidence intervals for the seasonal vaccine efficacy estimates against 
A(H3N2) are wide enough to encompass substantial vaccine efficacies, one plausible 
explanation for a potentially lower efficacy against A(H3N2) is the significant 
antigenic drift between the vaccine strain and the drifted A/Perth/16/09 (H3N2)-like 
viruses that circulated during the summer of 2010 in Hong Kong. It is possible that 
vaccine efficacy could have declined during the 6-month period between 
administration of the seasonal vaccine and local A(H3N2) activity, although the 
literature suggests that LAIV protection could last for a year or more [23,24]. The 
estimates of the efficacy of the seasonal LAIV against seasonal influenza, ARI and 
FARI are similar to estimates of the efficacy of seasonal trivalent inactivated 
influenza vaccination in school-age children in Hong Kong from a separate study 
conducted in the same year [17]. 
 
The major limitation of our study is that it was underpowered to identify vaccine 
efficacy with statistical significance, due to the moderate sample size and lower than 
expected attack rates of confirmed influenza. Incidence of H1N1pdm09 was low in 
children in 2010, following the first pandemic wave (June-October 2009) during 
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which around half of school-age children were estimated to have had H1N1pdm09 
infection [25]. Furthermore, our estimates of vaccine efficacy may be conservative 
given that some participating children may have been immune prior to vaccination. 
The prevalent seasonal A(H3N2) viruses in the summer of 2010 were antigenically 
similar to the A/Perth/16/09 (H3N2)-like virus that had circulated in Hong Kong in 
the summer of 2009 [15] and to which many children had been exposed during that 
period [16]. With only a small number of children aged 7-8 who had not previously 
been vaccinated, we could not explore whether vaccine efficacy was lower in these 
children. Other limitations of this report include the lack of a serologic endpoint, since 
it is unlikely that we were able to confirm all influenza infections by RT-PCR despite 
intensive prospective follow-up [16,17]. Finally, study subjects who received vaccine 
may have experienced milder illness and reduced viral shedding if infected with 
influenza, reducing the probability of confirming infection with laboratory testing. 
Herd immunity [26-28] is unlikely to have affected our results given the low 
participation rate in individual classes. Among children who did not participate in our 
study, uptake of the 2009 H1N1pdm09 vaccine and the 2009-10 seasonal influenza 
vaccine was very low [17,29]. 
 
Higher rates of adverse events reported for the H1N1pdm09 vaccine than the seasonal 
vaccine (Appendix Figure 2) are unlikely to reflect greater reactogenicity of the 
H1N1pdm09 vaccine because of the similarly high rates for the matching placebo. 
One possible explanation is that the earlier timing of H1N1pdm09/placebo 
administration coincided with colder weather or a period of co-circulation of other 
respiratory pathogens, although the latter is less likely if the H1N1pdm09 vaccine 
were to provide short-term immunity against other respiratory infections [30]. 
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Another explanation is greater awareness of symptoms during that period, or greater 
anxiety about receipt of a new vaccine. 
 
In conclusion, our results are consistent with the anticipated benefits associated with 
receipt of H1N1pdm09 and seasonal influenza vaccine. Our study demonstrated 
efficacy of seasonal vaccination against well-matched influenza B even when 
preceded by monovalent H1N1pdm09 vaccination, and limited adverse effects of 
vaccination. Following the pandemic, the seasonal A(H1N1) strain has been replaced 
in influenza vaccines by a H1N1pdm09 strain so that only one vaccine is required to 
protect against all strains predicted to circulate. In preparation for future pandemics, 
maximum benefit would be gained from timely availability of an effective vaccine. 
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Table 1. Baseline characteristics of study subjects by study arm. 
Characteristic Seasonal & 
H1N1 (n=272) 
H1N1 
(n=143) 
Seasonal 
(n=143) 
Placebo 
(n=145) 
p-value* 
 n (%) n (%) n (%) n (%)  
Female 144 (53) 76 (53) 73 (51) 76 (52) 0.98 
          
Age group          
7-8 years 99 (36)  44 (30) 41 (29) 45 (31) 0.37 
9-11 years 173 (64)  99 (70) 102 (71) 100 (69)  
          
Received influenza 
vaccination prior to the 
2008-09 season (%) 
61 (22) 
 
32 (22) 
 
38 
  
(27) 31 
 
 
(21) 
 
0.72 
 
          
Mean number of 
household members (sd) 
4.3 (1.1) 4.1 (1.1) 4.1 (1.0) 4.2 (1.0) 0.24 
 
          
Educational attainment of 
household head 
         
College 63 (23) 35 (24) 31 (22) 36 (25) 0.85 
Secondary or Primary 187 (69) 96 (67) 105 (73) 100 (69)  
Unknown 22 (8) 12 (8) 7 (5) 9 (6)  
 
* p-values estimated by chi-squared tests.
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Table 2. Incidence rates of confirmed influenza infections and acute respiratory illnesses among study subjects who received 2009 monovalent 
pandemic H1N1 (H1N1pdm09) vaccine and/or seasonal trivalent vaccine, or placebo. Incidence rates are estimated per 1,000 person-months of 
follow-up, with 95% confidence intervals. 
Outcomes 
H1N1pdm09 & 
seasonal H1N1pdm09 Seasonal Placebo p-value 
  (95%CI)  (95%CI)  (95%CI)  (95%CI)  
  (n=272)  (n=143)  (n=143)  (n=145)  
RT-PCR confirmed 
influenza: 
         
Pandemic A(H1N1 
pdm09) 
0.4 (0.0, 1.3) 0.0 (0.0, 0.6) 1.6 (0.0, 3.9) 0.0 (0.0, 0.6) 0.27 
Seasonal A(H3N2) 1.7 (0.0, 3.4) 1.6 (0.0, 3.9) 0.8 (0.0, 2.4) 2.4 (0.0, 5.2) 0.83 
Seasonal B 0.0 (0.0, 0.3) 5.8 (1.5, 10.0) 0.8 (0.0, 2.4) 7.3 (2.5, 12.1) <0.01 
FARI 57.1 (48.1, 67.7) 62.5 (49.9, 78.3) 68.3 (55.1, 84.7) 74.6 (60.8, 91.6) 0.23 
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ARI 
147.5 (132.6, 
164.0) 
140.7 (121.1, 
163.4) 
163.7 (142.5, 
188.1) 
189.9 (167.0, 
215.8) 
0.01 
* p-values calculated by Fisher’s exact tests for RT-PCR confirmed infections and Wald tests under Poisson regression for ARI and ILI. 
† FARI defined as fever ≥37.8ºC plus cough or sore throat; ARI defined as at least two of fever ≥37.8°C, sore throat, cough, headache, myalgia.
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Table 3. Vaccine efficacies against confirmed influenza, influenza-like illness and acute respiratory illness, with 95% confidence intervals. 
Live attenuated vaccines Against RT-PCR-confirmed influenza Against febrile acute 
respiratory illness† 
Against acute 
respiratory illness†  H1N1pdm09 A(H3N2) B 
Compared to placebo/placebo:      
(I vs IV): H1N1pdm09 plus 
seasonal  
n/a‡ 0.29 (-2.13, 0.84) 0.97 (0.49, 1.00) 0.24 (0.00, 0.41) 0.22 (0.08, 0.34) 
(II vs IV): H1N1pdm09  n/a‡ 0.32 (-2.99, 0.89) 0.21 (-1.06, 0.70) 0.16 (-0.14, 0.38) 0.26 (0.10, 0.39) 
(III vs IV): seasonal n/a‡ 0.66 (-2.21, 0.96) 0.89 (0.12, 0.99) 0.09 (-0.23, 0.32) 0.14 (-0.04, 0.29) 
      
Compared to matched placebo 
regardless of the other vaccine: 
     
(I/II vs III/IV): H1N1pdm09  0.65 (-2.81, 0.97) -0.04 (-2.66, 0.70) 0.51 (-0.26, 0.81) 0.18 (-0.01, 0.33) 0.18 (0.07, 0.28) 
(I/III vs II/IV): seasonal  n/a‡ 0.31 (-1.38, 0.80) 0.96 (0.67, 0.99) 0.11 (-0.09, 0.27) 0.07 (-0.05, 0.19) 
* Influenza vaccine efficacies derived by comparing incidence rates in study arms: I= H1N1pdm09 vaccine plus seasonal trivalent vaccine; II=H1N1pdm09 
vaccine plus placebo; III=seasonal trivalent vaccine plus placebo; IV=two doses of placebo. VE = (1-relative risk)×100. 
† FARI defined as fever ≥37.8ºC plus cough or sore throat; ARI defined as at least two of fever ≥37.8°C, sore throat, cough, headache, myalgia. 
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‡ could not be estimated due to an insufficient number of events. 
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Figure 1. Flow of subjects through the study 
 
 
 29 
Appendix Figure 1. Study timeline in relation to influenza detections reported by the 
World Health Organization reference laboratory at Queen Mary Hospital, Hong Kong. 
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Appendix Figure 2. Adverse events classified as mild or moderate reported by 
recipients of H1N1pdm09 vaccination or placebo (left) and seasonal vaccination or 
placebo (right). Statistically significant differences at p<0.05 are highlighted with an 
asterisk. 
 
 
  
 
 
